# US 2026/0216350 A1 · Insulin complexes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0216350 A1
- Document ID: US20260216350A1
- Status: Published application
- Kind: A1
- Application number: 19/146,172
- Filed: 2024-01-10
- Published: 2026-07-30
- Earliest claimed: 2023-01-11
- Assignees: University of Notre Dame du Lac
- Applicants: University of Notre Dame Du Lac
- Inventors: Matthew J. Webber; Yuanhui Xiang; Sijie Xian
- Web page: https://patentgrep.com/patent/US20260216350A1

## CPC

- A61K 47/595: {Polyamides, e.g. nylon (polyamino acids A61K47/62)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/28: Insulins
- A61K 47/54: the modifying agent being an organic compound
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07K 14/62: Insulins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described are complexes comprising insulin. The complexes described herein comprise insulin or a macromolecule attached to a glucose-binding diboronate motif (B1), and a macromolecule or insulin attached to a diol (D1). Further disclosed are methods of correcting blood glucose levels in a subject in need thereof, the methods comprising administering a complex described herein or a pharmaceutical composition comprising a complex described herein to the subject in need thereof.

## Claims

### Claim 1

A complex comprising:
insulin attached to B1 (insulin-B1) and a macromolecule attached to D1 (macromolecule-D1); or
insulin attached to D1 (insulin-D1) and a macromolecule attached to B1 (macromolecule-B1);
wherein:
B1 is
wherein:
BX, at each occurrence, is B(OH)2 or [B(OH)3]—;
G1, at each occurrence, is independently a pyridylene or a phenylene, wherein G1 is optionally substituted with 1-2 substituents independently selected from the group consisting of halogen, —CN, C1-4alkyl, —NO2, C3-4cycloalkyl, C1-2haloalkyl, —OC1-4alkyl, —OC3-4cycloalkyl, and —OC1-2haloalkyl, wherein each cycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, C1-4alkyl, and C1-2haloalkyl;
L12, at each occurrence, is independently a C1-6alkylene wherein optionally 1-2 methylene groups in the alkylene of L12 are independently replaced with —N(H)—, —O—, or —S—, wherein 2 methylene groups replaced with —N(H)—, —O—, or —S— are separated by two or more carbon atoms in the alkylene; and
G2 is phenylene, wherein G2 is optionally substituted with a first substituent selected from the group consisting of halogen, cyano, C1-6alkyl, C1-4haloalkyl, oxo, —OR2x, —N(R2x)2, —SR2x, —SO2R2x, —C(O)R2x, —C(O)OR2x, —C(O)N(R2x)2, —C1-6alkylene-OR2x, —C1-6alkylene-SR2x, —C1-6alkylene-N(R2x)2, —C1-6alkylene-SO2R2x, —C1-6alkylene-C(O)R2x, —C1-6alkylene-C(O)OR2x, and —C1-6alkylene-C(O)N(R2x)2, and optionally further substituted with 1-3 substituents independently selected from the group consisting of halogen, cyano, C1-4alkyl, C1-4haloalkyl, and —OR2x;
R2x, at each occurrence, is hydrogen, C3-4cycloalkyl, C1-2haloalkyl, —OC1-4alkyl, —OC3-4cycloalkyl, or —OC1-2haloalkyl, wherein each cycloalkyl is optionally substituted with 1-4 substituents independently selected from the group consisting of halogen, C1-4alkyl, and C1-2haloalkyl; and
D1 is a diol moiety comprising

### Claim 2 (depends on 1)

The complex of claim 1, wherein the complex comprises the insulin-B1 and the macromolecule-D1.

### Claim 3 (depends on 2)

The complex of claim 2, wherein the molar ratio of the insulin-B1 to the macromolecule-D1 is from 1:1 to 110:1.

### Claim 4 (depends on 1)

The complex of claim 1, wherein G2 is phenylene.

### Claim 5 (depends on 1)

The complex of claim 1, wherein
is:
wherein:
R1, at each occurrence, is independently halogen, —CN, C1-4alkyl, —NO2, C3-4cycloalkyl, C1-2haloalkyl, —OC1-4alkyl, —OC3-4cycloalkyl, or —OC1-2haloalkyl;
R2, at each occurrence, is independently —CN, C1-4alkyl, —NO2, C3-4cycloalkyl, C1-2haloalkyl, —OC1-4alkyl, —OC3-4cycloalkyl, or —OC1-2haloalkyl; and
X− is an anion having a net charge of −1.

### Claim 6 (depends on 5)

The complex of claim 5, wherein X− is Br−, Cl−, NO3−, H2PO4−, H2PO3−, HSO4−, HSO3−, H3C—SO3−, HCO3−, HCO2−, H3C—CO2−, HC2O4−, or TsO−.

### Claim 7 (depends on 6)

The complex of claim 6, wherein X− is Br− or Cl−.

### Claim 8 (depends on 1)

The complex of claim 1, wherein B1 is attached to the insulin by a linking moiety.

### Claim 9 (depends on 8)

The complex of claim 8, wherein the linking moiety comprises:

### Claim 10 (depends on 9)

The complex of claim 9, wherein the linking moiety comprises:
wherein n is 1 to 20.

### Claim 11 (depends on 1)

The complex of claim 1, wherein B1 is attached to the insulin's LysB29 residue.

### Claim 12 (depends on 1)

The complex of claim 1, wherein D1 is:

### Claim 13 (depends on 1)

The complex of claim 1, wherein the macromolecule is a dendrimer.

### Claim 14 (depends on 13)

The complex of claim 13, wherein the dendrimer is a polyamidoamine dendrimer, a polyethylenimine dendrimer, a polyester dendrimer, or a lysine dendrimer.

### Claim 15 (depends on 13)

The complex of claim 13, wherein the dendrimer is a 16-arm to 256-arm dendrimer.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising the complex of claim 1 and a pharmaceutically acceptable excipient.

### Claim 17 (depends on 1, 16)

A method of correcting blood glucose levels in a subject in need thereof, the method comprising: administering the complex of claim 1, or the pharmaceutical composition of claim 16, to a subject in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the subject in need thereof has diabetes.

### Claim 19 (depends on 17)

The method of claim 17, wherein the insulin-B1 is administered to the subject at 0.05 mg/kg to 10 mg/kg.

### Claim 20 (depends on 17)

The method of claim 17, wherein following administration of the complex or pharmaceutical composition, the subject has blood glucose levels of 40 mg/dL to 800 mg/dL.

### Claim 21 (depends on 17)

The method of claim 17, wherein following administration of the complex or pharmaceutical composition, the subject has corrected blood glucose levels for at least 1 day.

### Claim 22

(canceled)
